ESR2 and breast cancer: The use of an ERβ-specific agonist significantly decreases the expression and functional activity of ERα in MCF-7 breast cancer cells, accompanied by decreased transcription of a downstream effector, breast cancer-associated gene 2 (BCA2) [78].